Biopartners has received marketing authorization for the EU from the European Commission for its biosimilar medicinal product Valtropin, a recombinant human growth hormone used for the treatment of human growth deficiency in children and Turner’s Syndrome. Biopartners, jointly with LG Life Sciences, has co-developed a number of biopharmaceutical products including Valtropin and a sustained release formulation of Valtropin. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for Valtropin in Europe, Japan and other parts of Asia.

“We are delighted to have gained EU marketing authorization for Valtropin,” said Mr. Jean-Noel Treilles, chief executive officer of Biopartners. “As the first product in our broad and advanced pipeline to gain authorization, this marks a major milestone for Biopartners. We aim to make Valtropin available to healthcare professionals and patients through our distributors before the end of the year. Biopartners is currently developing a sustained release version of Valtropin that is currently in Phase III trials.”